

Index

Note: page numbers followed by *f* refer to figures. Page numbers followed by *t* refer to tables.

A

- A1c. *See* hemoglobin A1c
- α -adrenergic receptor, 89
- α -adrenoreceptor blocker, 48
- α -adrenergic blocker, 107
- abacavir, 71*t*
- acarbose, 110, 114
- ACE inhibitor. *See* angiotensin-converting enzyme (ACE) inhibitor
- α -cell, 8–9
- acetaminophen, 97–98
- acetoacetate, 89
- acetyl CoA carboxylase (ACC), 7
- acetyl-coenzyme A (acetyl CoA), 6*f*, 7, 89
- acromegaly, 99
- Actos Now for the Prevention of Diabetes (ACT NOW), 110*t*, 111
- adenosine triphosphate (ATP)–sensitive potassium channel (KATP), 8
- adenylate cyclase, 89
- adipocyte, 7, 24
- adiponectin, 7, 97
- adiponectin gene, 87
- adipose tissue, 89
- African American population, 5
- age, 4
- α -glucosidase inhibitor, 27, 70
- α -Interferon, 15*t*
- Akt/protein kinase B (PKB), 6
- alcohol/alcoholism, 17–18, 85
- alcoholic pancreatitis, 85
- aldosterone, 24
- allograft, 26–27
- alloxan, 17
- Ambrose, PG, 68
- American Association of Clinical Endocrinologists (AAACE), 101
- American Cancer Society (ACS), 40
- American Diabetes Association (ADA), 1, 2*f*, 85, 100–102, 112
- American Diabetes Association Consensus Panel, 77
- American Heart Association (AHA), 40
- American Medical Association (AMA), 109
- American Urological Association (AUA), 40
- amphetamine, 89–90
- amprenavir, 69
- amputation, 62
- anabolic steroid, 39
- anakinra, 28
- androgen, 36–38
- androgen-deprivation therapy (ADT), 40
- angiogenesis, 62
- angiotensin-converting enzyme (ACE) inhibitor, 47–49, 107
- angiotensin receptor blocker (ARBs), 48–49, 107
- Anglo- Scandinavian Cardiac Outcomes Trial (ASCOT), 47

anorexia, 88
 antibiotic, 15*t*, 67–68
 anticonvulsant, 99
 antidepressant, 15*t*, 78–80, 107, 108*f*
 antidepressant-associated diabetes, 80
 antidiabetic medication, 78, 107
 antihyperglycemic agent, 102
 antihypertensive agent, 47–50, 108*f*
 antihypertensive and lipid-lowering treatment to prevent Heart Attack Trial (ALLHAT), 47
 antimalarial agent, 68
 antimicrobial drug, 67–71, 108*f*
 antiprotozoal drug, 17
 antipsychotic, 15*t*, 108*f*, 114
 antipsychotic agent (typical), 75
 antipsychotic associated diabetes (APAD), 75
 antirejection immunosuppressive therapy, 27
 antiretroviral agent, 15*t*, 69–70
 antiretroviral armamentarium, 70
 antiretroviral-associated diabetes, 69
 antiretroviral therapy, 114
 apoptosis, 21–22, 111–112
 aripiprazole, 76
 arterial revascularization, 58
 arteriolar vasodilator diazoxide, 50
 asenapine, 76
 Asian population, 108
 aspirin, 97
 asthma, 22, 55
 atenolol, 48
 Atherosclerosis Risk in Communities (ARIC) study, 48
 atypical antipsychotic agents (SGAs), 75–78, viii
 Australian Diabetes Society/
 Australian Diabetes Educators Association, 113
 autoimmune disorder, 27
 autoimmune mediated mechanism, 3

B

β 2-adrenergic agonist, 55
 β 3-adrenergic receptor, 89
 Bacteroidetes, 67
 β -adrenergic agonist, 55, 107
 β -adrenergic blocker, 107
 β -adrenergic receptor, 89
 β -adrenoreceptor blocker, 48
 β -agonist, 15*t*, 108*f*
 β -blocker, 15*t*, 16, 47–49, 107
 β -cell, 2–4, 6*f*, 8–9, 25, 27–28, 69. *See also* pancreatic β -cell
 β -cell apoptosis, 21–22, 27–28
 Beck Depression Index (BDI), 78–79
 β -endorphin, 87–88
 bezafibrate, 61
 bilateral atherosclerotic renovascular disease, 49
 bile acid sequestrant, 61–62
 blonanserin, 76
 blood flow, 16
 blood glucose level, 16
 BMI (body mass index), 60, 77, 86
 β -oxidation, 7, 99
 Bradford Hill, Austin, 16
 Bradford Hill's criteria, 16–17, 75
 brexpiprazole, 76
 bromocriptine (BQR), 10
 bronchodilators, 55
 bupropion, 86, 88

C

calcineurin inhibitor, 24–27
 calcium, 8
 calcium-channel blocker (CCB)–ACE inhibitor, 47
 calcium-channel blocker CCBs, 49, 107
 calorie, 7
 cAMP-dependent protein kinase, 89
 Canadian Normoglycemia Outcomes Evaluation (CANOE), 110*t*, 111
 Canary Health, 109

- cancer, 40
 cannabinoid, 86–87
 cannabinoid (CB) type 1 receptor, 87
 cannabinoid (CB) type 2 receptor, 87
 carbamazepine, 99
 carbohydrate, 7, 55
 cardiac complication, 100
 cardiovascular disease, 40, 62, 67
 cardiovascular event, 58
 carnitine palmitoyl transferase (CPT)-1, 7
 carnitine palmitoyl transferase (CPT)-2, 7
 carvedilol, 48
 catecholamine, 55, 89, 99, 108*f*
 catecholamine-induced hyperglycemia, 50
 catecholamine-induced insulin resistance, 55
 causation, 16–17
 ceftriaxone, 69
 Centers for Disease Control and Prevention (CDC), 4, 18, 109
 central dopaminergic pathways, 10
 central nervous system (CNS), 10
 cephalosporin, 68
 Chadban, S., 27
 Cheung, NW, 100
 chlorpropamide alcohol flushing, 87
 chlorthalidone, 47
 cholesterol, 58. *See also* high-density lipoprotein (HDL) cholesterol; low-density lipoprotein (LDL) cholesterol
 cholesterol 7- α -hydroxylase, 61
 chronic obstructive pulmonary disease, 55
 cimetidine, 17
 ciprofloxacin, 68
 circulating inflammatory marker, 58
 Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), 75–76
 clonidine, 50
 cocaine, 89–90
 colesevelam, 61–62
 community resource, 109
 comorbid condition, 18, vii
 complication, 1, 62
 Conn, JW, 24
 continuous glucose monitoring (CGM), 98
 counterregulatory hormones, 89
 Cox proportional hazard models, 78
 C-peptide, 88
 C-reactive protein, 58
 cyclosporine, 15*t*, 25, 27
 cytokine, 27–28, 62, 97, 101
 cytosol, 6–7
 Czaskowska, JB, 27
- D**
 Da Qing study, 110*t*
 Davis, TM, 62
 dawn phenomenon, 100
 delavirdine, 71*t*
 demographic factor, 4–5
 de novo hepatic lipogenesis, 57
 depression, 78–79
 desogestrel-containing OC, 36
 De Wit, S, 70
 dexamethasone, 22
 dextroamphetamine, 89
 diabetes. *See also under specific type*
 antibiotic exposure, 67
 classification, 1–10
 complication, 62
 diagnosis, 1–10
 education, 77, 107
 management, 26
 mellitus, 6*f*
 pathophysiology, 1–10
 pharmacoprophylaxi, 113–115, vii
 prevention, 26, 39, 60, 108–110, 112–113
 risk and medication, 15–18
 statistics, 1–2

diabetes-associated type IV renal tubular acidosis, 49
 Diabetes Prevention Program (DPP), 35, 38, 60, 78–79, 85, 108–110, 113–114
 diabetes prevention studies, 110*t*
 Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM), 110*t*, 111
 diabetic autonomic neuropathy, 49
 diabetic ketoacidosis (DKA), 18, 28, 75, 89, 99
 diabetic nephropathy, 26
 diabetic neuropathy, 49, 62, 85, 88–89
 diabetogenic therapy, 114
 diacylglycerol (DAG), 6*f*, 7
 diacylglycerol-acetyl transferase 2, 57
 diazoxide, 15*t*, 49–50
 didanosine, 69
 dietary intervention, 107, 109
 diethylpropion, 90
 dihydrotestosterone (DHT), 38, 40
 Ding, EL, 37–38
 dipeptidyl peptidase-4 (DPP-4) inhibitor, 114
 disease, 2, 16
 diuretic, 15*t*, 47, 49
 dopamine, 9*f*, 89–90
 dopamine agonist bromocriptine-QR, 114
 DPP Outcomes Study, 79, 114
 DPS, Finland, 110*t*
 drug-induced diabetes, 114
 drug-induced hyperglycemia, 108
 drug interaction, 115
 drug-related diabetes, 18
 dysglycemia, 68–69, 100
 dyslipidemia, 57–58, 61, 107

E
 education, 77, 107
 efavirenz, 71*t*
 elderly population, 100
 emtricitabine, 71*t*
 endocannabinoid receptor blocker, 86
 endoplasmic reticulum stress (ER), 21
 endothelial dysfunction, 98
 endothelial function, 58, 62, 86
 environmental interaction, 3, 5
 epilepticus, 99
 epinephrine, 55
 estradiol, 35, 37*t*, 38
 estrogen, 35
 estrogen replacement therapy, 35–36
 estrone, 38
 estrone sulfate, 35
 ethinyl estradiol, 36
 ethnicity, 5
 etomoxir, 22–23
 European American population, 5
 Expert Panel of the American Diabetes Association, 80

F
 fasting plasma glucose (FPG), 1, 2*f*, 26, 59
 fat, 7
 fatty acid, 7, 47, 100. *See also* nonesterified fatty acids (NEFAs)
 fenofibrate, 61
 Fenofibrate and Event Lowering in Diabetes (FIELD) study, 62
 fibrate, 61–62
 Firmicutes, 67
 fludrocortisone (Florinef), 24
 fluoroquinolone, 68–69
 fluoroquinolone-associated hyperglycemia, 68–69
 follicle-stimulating hormone (FSH), 36–37

food intake, 88
 fosamprenavir, 71*t*
 free fatty acid, 47, 100

G

gabapentin, 99
 gastrointestinal disturbance, 114
 gatifloxacin, 68–69
 gemfibrozil, 61
 gender, 4
 General Practice Research Database, 59
 genetic factor, 2–3, 5, 22
 gestational diabetes, 2, 22
 glandular disorder, 2
 glinide, 27
 gliptin, 27
 glucagon, 8–9
 glucagon-like peptide [GLP]-1, 9
 glucagon-like peptide-1 (GLP-1) receptor agonist, 114
 glucagon secretion, 9*f*
 glucagon suppression, 101
 glucocorticoid, 15*t*, 89
 glucocorticoid-induced diabetes, 23
 glucocorticoid-induced dysglycemia, 21
 glucocorticoid steroid, 21–24
 gluconeogenesis, 15*t*, 57, 97
 glucoregulation, 24, 36–38
 glucoregulatory system, 100
 glucosamine, 97–98
 glucose, 1, 8, 16, 55, 108*f*, vii
 glucose-6-phosphatase activity, 98
 glucose-dependent insulinotropic peptide (GIP), 9
 glucose intolerance, 99
 glucose oxidation, 100
 glucose reabsorption, 9*f*
 glucose tolerance, 57
 glucose transporter molecules (GLUT1), 9
 glucose transporter molecules (GLUT2), 9

glucose transporter molecules (GLUT4), 6–7, 59, 69
 glycemic control, 58
 glycemic target, 101
 glycerol, 89
 glycogenolysis, 55
 glycolytic enzyme activity, 87
 gonadotropin-releasing hormone agonist, 40
 gonadotropin-releasing hormone analog, 35–40
 GPR109A (Gi-protein-coupled receptor), 57
 growth hormone (GH), 15*t*, 99–100
 growth hormone-induced hyperglycemia, 100
 guanabenz, 50
 guanfacine, 50
 gut cell, 100
 gut flora, 15*t*, 67–68
 gut microbiomics, 68

H

HbA1c. *See* hemoglobin A1c
 HDL cholesterol. *See* high-density lipoprotein (HDL) cholesterol
 head trauma, 99
 Health Improvement Network, 67
 heart failure, 47
 Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) study, 58
 heart rate, 115
 hemoglobin A1c
 CATIE study, 76*t*
 colesevelam, 61
 diabetes diagnosis, 1
 diagnostic criteria, 2*f*
 gonadotropin-releasing hormone (GnRH) agonist, 40
 JUPITER trial, 60
 nicotine, 86

- race and ethnicity, 5
 - salsalate, 97
 - statin, 59
- hepatic bile acid synthesis, 61
- hepatic dysfunction, 70–71
- hepatic gluconeogenesis, 89
- hepatic glucose production (HGP), 4, 8–9, 21, 47, 98
- hepatic injury, 70
- hepatic lipase activity, 86
- hepatitis C, 28, 99
- hepatocyte, 7, 89, 99
- heroin, 88
- high-density lipoprotein (HDL)
 - cholesterol, 47–48, 58, 77, 85
- highly active antiretroviral therapy (HAART), 69–71
- Hispanic American population, 5
- histocompatibility (HLA) gene, 2–3
- HIV-1 protease inhibitors (PIs), 69–70
- HIV-AIDS, 70
- HIV-associated enteropathy, 70
- HIV-associated lipodystrophy, 69, 71
- HIV cachexia, 100
- HIV-infected patient, 17, 69–70
- HIV nephropathy, 70
- HMG-coenzyme A reductase inhibition, 59
- hormone replacement therapy (HRT), 38
- hormone-sensitive lipase, 57, 89
- hydralazine, 50
- hyperaldosteronism, 24
- hypercortisolemia, 78
- hyperglucagonemia, 8–9
- hyperglycemia
 - arteriolar vasodilator diazoxide, 50
 - cocaine, 89
 - diabetes manifestation, 1
 - drug-associated diabetes, 16
 - drug-induced, 15*t*, 108
 - drug-related, 18
 - glucocorticoid therapy, 22, 24
 - GnRH agonist, 40
 - growth hormone, 100
 - inpatient, 100–101
 - methadone, 87
 - nevirapine, 71
 - phenytoin, 99
 - progesterin-containing oral contraceptive, 36
 - quinolone, 68–69
 - renal glucose reabsorption, 9
 - total parenteral nutrition, 100–101
 - type 2 diabetes, major pathophysiological defects in, 9*f*
 - verapamil, 49
- hyperinsulinemia, 2, 88
- hyperinsulinemic euglycemic clamp studies, 48
- hyperkalemia, 49
- hyperphagia, 88
- hypertension, 18, 36, 47–50, 107, 115
- hyperthyroidism, 98–99
- hyperthyroidism-associated dysglycemia, 98
- hypertriglyceridemia, 61
- hypoglycemia
 - alcohol, 85
 - aspirin, 97
 - β -blocker, 48
 - fluoroquinolone, 68–69
 - iatrogenic, 114
 - intensive glycemic control, 101
 - pentamidine-induced diabetes, 17
 - total parenteral nutrition, 102
 - tramadol, 88–89
 - tumor necrosis factor (TNF)- α , 27
- hypogonadism, 88
- hypogonadotropic hypogonadism, 36–37
- hypoinsulinemia, 15
- hypokalemia, 15, 15*t*, 24, 47

- hypothalamic-pituitary-adrenal axis, 78
- hypothyroidism, 99
- I**
- iatrogenic hyperglycemia, 107
- iatrogenic hypoglycemia, 114
- interferon-associated diabetes, 28
- iloperidone, 76
- immunological disorders, 27
- immunomodulatory agent, 24–28, 108*f*
- immunosuppressive agent, 25–26
- impaired fasting glucose (IFG), 1–2, 4, 23, 60, 112–113
- impaired glucose tolerance (IGT), 1–2, 4, 8, 23, 97, 110–113
- impaired insulin action. *See* insulin resistance
- incretin, 8–9, 100–101, 112
- incretin deficiency, 9*f*
- incretin-mimetic drugs, 112
- Indian Diabetes Prevention Program (IDPP)-1, 110*t*, 111
- Indian Diabetes Prevention Program (IDPP)-2, 110*t*, 111
- Indian Health Services (IHS), 113
- indinavir, 69
- inflammatory cytokine, 24
- inhaled agent, 55
- insulin
- action, 15*t*, 87, 98, 100
 - antipsychotic drugs, in patients receiving, 78
 - biosynthesis, 21
 - exogenous, 71
 - glucocorticoid therapy, 24
 - IV insulin infusion, 102
 - naloxone, 88
 - new-onset diabetes after transplantation, 26–27
 - rapid-acting analog, 102
 - sensitivity, 7, 35, 48, 57, 87, 97
 - sensitizer, 23, 27
 - short acting, 102
 - synthesis, 68
- insulin-deficient diabetes, 17–18
- insulin-induced hypoglycemia, 48
- insulinoma, 50
- insulin receptor substrates (IRS), 6
- insulin resistance, 6–7
- antiretroviral-associated diabetes, 69
 - diabetes classification, 2
 - glucocorticoid, 21
 - glucocorticoid-induced, 23
 - glucosamine, 97
 - GnRH agonists, 40
 - growth hormone, 100
 - hypokalemia, 47
 - interferons, 28
 - new-onset diabetes after transplantation, 25
 - nicotine, 86
 - nucleoside analog, 69
 - opioid addiction, 88
 - oral contraceptive-induced, 36
 - renin-angiotensin-aldosterone system, 48
 - sex hormone binding globulin, 38
 - steroid-induced diabetes, 15–16
 - theophylline, 55
 - thiazide diuretic, 47
 - tumor necrosis factor (TNF)- α , 27
 - type 2 diabetes, 4, 9*f*
- insulin secretion, 8
- arteriolar vasodilator diazoxide, 50
 - drugs that inhibit, 15
 - gatifloxacin, 68
 - glucocorticoid, 21
 - hyperglycemia, 16
 - hypokalemia, 47–48
 - impaired, 4, 9*f*
 - incretin, 101
 - interleukin-1 receptor antagonist, 27–28
 - mineralocorticoid, 24

opioid, 87
 protease inhibitor, 69
 statin, 59
 thyroid hormone, 98
 intensive care units (ICUs), 101
 intensive insulin therapy, 101
 interferons (IFNs), 28
 interferon therapy, 99
 interleukin-1 receptor antagonist,
 27–28
 intestinal bacteria, 67
 intestinal incretin-secreting cell, 100
 intestinal microbial flora, 16, 68
 isoproterenol, 55

J

JUPITER trial, 58–61

K

KATP channel, 50, 68
 ketoacidosis, 17, 90, 99, 115. *See also*
 diabetic ketoacidosis (DKA)
 kidney transplant, 26
 Krebs cycle, 6f, 7, 8f

L

labetalol, 48
 lactate, 55
 lactic acidosis, 70–71
 lamivudine, 71t
 laropiprant, 58
 LDL cholesterol. *See* low-density
 lipoprotein (LDL) cholesterol
 levofloxacin, 68–69
 lifestyle, 60, 70, 77, 108–110
 lipid-lowering drug, 57–62, 108f
 lipatrophy, 69, 71
 lipodystrophy, 69, 71
 lipohypertrophy, 69
 lipolysis, 7, 9f, 21, 55, 57, 100
 lipoprotein level, 86
 lipotoxicity, 7

liraglutide, 114
 liver enzyme, 71
 long-chain fatty acyl coenzyme A
 (LCFA-CoA), 6f, 7
 lopinavir, 71t
 low-density lipoprotein (LDL)
 cholesterol, 61, 98
 lupron, 40
 lurasidone, 76–77
 luteinizing hormone (LH), 36

M

macrolide, 68
 malonyl CoA, 6f, 7
 marijuana, 86–87
 Mather, KJ, 38
 MEDEM (monitoring, education,
 diet, exercise, medication), 26,
 107
 medication. *See also under specific*
type or name
 antidiabetic, 78, 107
 antiobesity, 90
 diabetes prevention, 109–110,
 112–113
 diabetes risk: general mechanism,
 15–18
 HIV-infected patient, 70–71
 limitations of, 111–112
 lipid-lowering, 57–62
 oral, 55
 type 1 diabetes, 17–18
 type 2 diabetes, 18
 menopausal women, 36
 mephedrone, 90
 metabolic acidosis, 75
 metabolic syndrome, 60, 86
 Metabolic Syndrome in Men
 (METSIM) cohort study, 59
 metformin, 17, 23, 27, 70–71, 79–80,
 85, 110–114
 methadone, 87
 methamphetamine, 89

- methylenedioxy-methamphetamine
 (MDMA or Ecstasy), 89–90
 methylxanthine, 55
 metoprolol, 48
 metreleptin, 71
 Mexican American population, 5
 microalbuminuria, 49, 62
 microvascular complication, 57, 62
 mineralocorticoid, 24
 minoxidil, 50
 mitochondrial dysfunction, 69
 monitoring, 77
 monogenic syndrome, 2
 monozygotic (identical) twins, 3
 moxifloxacin, 68
 myocardial infarction, 47, 58
 myocyte, 7
- N**
 naloxone, 87–89
 naltrexone, 88
 National Health and Nutrition
 Examination Survey
 (NHANES), 4–5, 86
 National Health and Nutrition
 Examination Survey
 (NHANES) III, 86
 National Institutes of Health (NIH),
 4, 75
 NAVIGATOR trial, 48, 110*t*, 111
 nelfinavir, 69
 neogenesis, 112
 nephropathy, 26
 neuropathic pain, 99
 neuropathy, 49, 62, 85, 88–89
 neuropsychiatric reaction, 115
 neurosurgery, 99
 nevirapine, 71
 new-onset diabetes, 48, 49*f*, 86
 new-onset diabetes after
 transplantation (NODAT),
 25–27
 niacin, 58
- NICE-SUGAR (Normoglycemia
 in Intensive Care Evaluation-
 Survival Using Glucose
 Algorithm Regulation) study,
 101
 nicotinamide, 17
 nicotine, 86
 nicotinic acid, 15*t*, 57–58, 107
 nitric oxide synthase, 62
 nondiabetic ketoacidosis, 99
 nonesterified fatty acids (NEFAs), 7,
 55, 57, 89
 non-Hispanic black population, 5
 non-Hispanic white population, 5
 nonketotic hyperosmolar syndrome,
 89
 non-nucleoside RT inhibitor, 71*t*
 nonsteroidal anti-inflammatory
 drugs (NSAIDs), 15*t*, 97–98
 norepinephrine, 89–90
 norepinephrine reuptake inhibitors,
 79
 nrtiretroviral agents, 71
 nucleoside analog, 69–70, 71*t*
 nucleoside RT inhibitor, 71*t*
 nutrient flux, 15*t*
- O**
 obesity, 67, 86, 88
 obesogenic regimen, 114
 olanzapine, 75–76
 opioid, 87–89
 opioid-associated obesity, 88
 oral antidiabetic medication, 71
 oral contraceptive (OC), 35–36
 oral contraceptive-induced diabetes,
 36
 oral glucose tolerance test (OGTT),
 1, 2*f*, 26, 35–36, 113
 oral medication, 55
 organic cation transporter 1
 (OCT1), 17
 organ transplantation, 24–25, 114
 orlistat, 110, 110*t*, 114

osteoarthritis, 97
 over-the-counter decongestant, 55
 oxidative stress, 101
 oxidative stress marker, 58

P

paliperidone, 76
 pancreas, 2
 pancreatic α -cell, 8
 pancreatic β -cell, 2, 4, 8, 15, 17, 50, 68, 88, 111–112
 pancreatic β -cell apoptosis, 27–28
 pancreatic islet cell, 28
 pancreatitis, 17–18, 85, 115
 pancreatotoxic, 15*t*
 parenteral medication, 55
 Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study, 4–5
 pediatric population, 100
 penicillin, 67
 Penner, EA, 86
 pentamidine, 15*t*, 17
 pentamidine-induced diabetes, 17
 pentamidine-induced hypoglycemia, 50
 peripheral glucose utilization, 21, 89
 peripheral neuropathy, 62
 peripheral vasodilator, 49–50
 peroxisome proliferator-activated receptor α , 61
 peroxisome proliferator-activated receptor γ , 61
 perphenazine, 75–76
 pharmacoprophylactic trials, 114
 phenolic moiety, 98
 phentermine, 89–90
 phenytoin, 99
 phosphatidylinositol 3-kinase (PI3-kinase), 6
 phosphodiesterase, 55
 physical activity, 107–108
 Pima Indian population, 4–5, 8
 pioglitazone, 110–111
 Pioglitazone in the Prevention of Diabetes (PIPOD), 111
 plasma lipoprotein, 50
 pleiotropic effect, 58
 Pneumocystis carinii pneumonia (PCP), 17
 postmenopausal women, 38, 59
 post-transplant diabetes, 24–27
 potassium, 24
 prazosin, 48
 prediabetes
 diagnosis, 1–2
 double, 113
 GH-induced hyperglycemia, 100
 GnRH agonists, 40
 interferons, 28
 lifestyle intervention, 108
 medication limitation, 111
 metformin, 80, 113
 nicotinic acid, 57–58
 pretransplant period, 26
 race and ethnicity, 5
 ramipril, 48
 steroid therapy, 21
 type 2 diabetes, pathophysiology of, 4
 pregnancy, 2
 premenopausal women, 35, 38
 pretransplant lifestyle counseling, 26
 Prevent Diabetes STAT (Screen/Test/Act Today), 109
 probiotic, 68
 progestin, 35–36
 proliferative retinopathy, 62
 prophylactic therapy, 113–114
 prophylaxis, 99
 prostate cancer, 40
 protease inhibitor, 71*t*
 protein kinase C (PKC), 6*f*, 7
 psychostimulant drugs, 89–90

Q

quetiapine, 75–76
 quinolone, 67–68
 quinolone-associated diabetes, 68

R

race, 5
 ramipril, 48
 random blood glucose (RBG), 2*f*
 randomized controlled trial, 16–17, 109–110
 recreational drug, 85–90, 108*f*
 refractory *Pneumocystis jirovecii* pneumonia (PJP), 17
 renal dysfunction, 68–69, 115
 renal failure, 49, 100
 renal glucose reabsorption, 9
 renin-angiotensin-aldosterone system, 48
 retinopathy, 62
 reverse transcriptase inhibitor, 69, 71*t*
 rimonabant, 86–87
 risk, 22–23
 risk factor, 6*t*, 16–17, 108
 risk reduction, 107–115
 risperidone, 75–76
 ritonavir, 69, 71*t*
 rosiglitazone, 110–111
 rosuvastatin, 58, 60

S

salicylate, 97–98
 salsalate, 97–98
 saquinavir, 71*t*
 Sattar, N, 61
 schizophrenia, 75–76, 108
SEARCH for Diabetes in Youth, 4
 secretagogue, 27
 seizure, 99
 selective glucocorticoid receptor agonists (SEGRAs), 23

selective serotonin reuptake inhibitors (SSRIs), 78–79
 self-blood glucose monitoring, 23, 107
 self-monitoring behavior, 109
 sepsis, 100
 serine residue, 7
 serotonin, 79, 89–90
 sertindole, 76
 sex hormone binding globulin (SHBG), 36–38
 sex steroid, 35–40
 SHIELD study, 5
 short stature, 100
 skeletal muscle cell, 24
 smoking, 16–17, 36, 86
 sodium glucose cotransporter 2 (SGLT2) inhibitors, 114
 sodium glucose cotransporters (SGLT)-1, 9
 sodium glucose cotransporters (SGLT)-2, 9
 statin, 58–62
 statin-induced diabetes, 59–60
 stavudine, 69–70, 71*t*
 steroid, 25, 27, 108*f*. *See also* sex steroid
 steroid-induced diabetes, 15, 21–22, 27
 steroid-induced dysglycemia, 78
 steroid-induced insulin resistance, 25
 steroid sex hormone, 38
 steroid therapy, 114
 STOP-NIDDM (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus), 110, 110*t*
 streptozotocin, 17
 stress hormone, 86
 stroke, 58
 sulfonylurea, 27, 110
 surgical resection, 2
 switching, 71, 78
 sympathomimetic drug, 55
 synarel, 40

Systolic Hypertension in the Elderly Patients (SHEP), 47

T

tacrolimus, 15*t*, 25–27
 temafloxacin, 68
 tenofovir, 71*t*
 terazosin, 48
 terbutaline, 55
 testosterone (T), 36–39
 theophylline-induced hypokalemia, 55
 thiazide, 107
 thiazide diuretic, 15*t*, 47–48
 thiazolidinediones (TZDs), 23, 27, 70–71, 110–111, 114
 Third National Health and Nutrition Examination Survey (NHANES 1988–1994), 35–36
 threonine residue, 6*f*, 7
 thyroid hormone, 98–99
 thyrotoxicosis, 99
 tobacco, 16–17, 36, 86
 tonic-clonic, 99
 total parenteral nutrition (TPN), 15*t*, 100–102
 total parenteral nutrition (TPN)-induced hyperglycemia, 100–102, vii
 tramadol, 88
 tramadol-associated hypoglycemia, 89
 trans-differentiating endoderm-derived cell, 112
 transplant immunosuppression, 107
 transplant recipient, 17, 22
 treatment-emergent diabetes, 17, 22, 28, 47, 100
 trelstar, 40
 tricyclic antidepressants (TCAs), 78–79
 triglyceride, 47–48, 89
 triphasic oral contraceptive, 36

tumor necrosis factor (TNF)- α , 27
 twin, 3
 2-deoxy-D-[1-3H] deoxyglucose, 87
 type 1 diabetes, 2–4, 8–9, 17–18
 type 2 diabetes
 antidepressant, 79
 antipsychotic associated diabetes, 75
 classification, 2–3
 colesevelam, 61
 drugs associated with, 18
 estradiol, 35
 glucagon hypersecretion, 8–9
 growth hormone, 99
 men, 35
 pathophysiological defects in, 9*f*
 pathophysiology of, 4
 prediabetes and, 2
 risk factor, 6*t*
 salsalate, 97
 testosterone level, 37

U

U.K. General Practice Research Database, 79
 uric acid, 97–98
 urinary albumin, 98
 U.S. Food and Drug Administration (FDA), 39–40, 59, 61, 76–77, 88, 98, 112
 U.S. Veterans Administration (VA), 40

V

vaccination model, 112
 Vacor (N-3 pyridylmethyl-N' 4 nitrophenyl urea), 15*t*, 17
 valproate, 99
 valsartan, 49
 van den Berghe, G, 101
 vantas, 40
 varenicline, 86
 vasoconstrictor, 16, 86

venous thromboembolism, 60–61
Veterans Administration, 69

W

weight, 76*t*, 77
weight gain, 99, 108
weight loss, 109, 113
white blood cell triglyceride, 97
Women's Health Initiative (WHI),
59–60

X

XENical in the Prevention of
Diabetes in Obese Subjects
(XENDOS) study, 110

Y

YMCA, 109

Z

zidovudine, 69, 71*t*
ziprasidone, 75–76
zoladex, 40